Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins

Oncolytic herpes simplex viruses (oHSVs) have been approved for clinical usage and become more and more popular for tumor virotherapy. However, there are still many issues for the oHSVs used in clinics and clinical trials. The main issues are the limited anti-tumor effects, intratumor injection, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiao-Qin, Xin, Hong-Yi, Lyu, Yan-Ning, Ma, Zhao-Wu, Peng, Xiao-Chun, Xiang, Ying, Wang, Ying-Ying, Wu, Zi-Jun, Cheng, Jun-Ting, Ji, Jia-Fu, Zhong, Ji-Xin, Ren, Bo-Xu, Wang, Xian-Wang, Xin, Hong-Wu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282442/
https://www.ncbi.nlm.nih.gov/pubmed/30799657
http://dx.doi.org/10.1080/10717544.2018.1534895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282442/
https://www.ncbi.nlm.nih.gov/pubmed/30799657
http://dx.doi.org/10.1080/10717544.2018.1534895

Ejemplares similares